Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators.

Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29482983
2.

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients.

Ruzzo A, Graziano F, Galli F, Giacomini E, Floriani I, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M.

Sci Rep. 2014 Nov 5;4:6828. doi: 10.1038/srep06828.

3.

Developing a decision-making model based on an interdisciplinary oncological care group for the management of colorectal cancer.

Genovesi D, Mazzilli L, Trignani M, DI Tommaso M, Nuzzo A, Biondi E, Tinari N, Martino MT, Innocenti P, DI Sebastiano P, Mazzola L, Lanci C, Neri M, Laterza F, Marino M, Ferrini G, Spadaccini A, Filippone A, DI Giandomenico E, Marulli A, Palombo G, Sparvieri A, Marchetti A, Pizzicannella G, Petrini F, DI Felice M, Ottaviani F, Monteodorisio A, DI Nicola M, Cefaro GA.

Anticancer Res. 2014 May;34(5):2525-31. Erratum in: Anticancer Res. 2014 Jun;34(6):3232.

PMID:
24778070
4.

Paralytic ileus associated with capecitabine.

Laudadio L, Biondi E, D'Ostilio N, Cesta A, Di Giandomenico F, Forciniti S, Nuzzo A.

Tumori. 2008 Sep-Oct;94(5):742-5.

PMID:
19112951
5.

Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer.

Recchia F, Saggio G, Nuzzo A, Biondi E, Di Blasio A, Cesta A, Candeloro G, Alesse E, Rea S.

J Immunother. 2006 Jan-Feb;29(1):87-94.

PMID:
16365604
6.

Oxaliplatin fractionated over two days with bimonthly leucovorin and 5-fluorouracil in metastatic colorectal cancer.

Recchia F, Rea S, Nuzzo A, Lalli A, Di Lullo L, De Filippis S, Saggio G, Biondi E, Massa E, Mantovani G.

Anticancer Res. 2004 May-Jun;24(3b):1935-40.

7.

Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma.

Palmieri G, Montella L, Milo M, Fiore R, Biondi E, Bianco AR, Martignetti A.

Am J Clin Oncol. 2002 Jun;25(3):224-6.

PMID:
12040276

Supplemental Content

Loading ...
Support Center